| Vetoquinol

322 publications

Name	Date	Type
A visionary strategy The key steps of a visionary strategy	03/04/2023	Press releases communication
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) Essentials sales: €304m (up 4.5% as reported) EBIT before depreciation of acquired assets: €99m (18.3% of sales) Net income - Group share: €48m (8.9% of sales) EBITDA: €118m (21.9% of sales) Free cash-flow: €63m	23/03/2023	Public releases
Serving animal Health - 90 years Serving animal Health for over 90 years	06/03/2023	Press releases communication
Buyback programs - February 2023 Monthly communication regarding buyback programs	06/03/2023	Description of buyback programs
Buyback programs - January 2023 Monthly communication regarding buyback programs	07/02/2023	Description of buyback programs
In 2023 Vetoquinol celebrates its 90th anniversary. - 90 years The story of an incredible family saga. From a regional pharmaceutical laboratory to a world leader in animal health.	31/01/2023	Press releases communication
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) Annual Sales of Essential products: €304 million (up 4.5% as reported)	18/01/2023	Public releases
Buyback programs - december 2022 Monthly communication regarding buyback programs	04/01/2023	Description of buyback programs
Buyback programs - november 2022 Monthly communication regarding buyback programs	08/12/2022	Description of buyback programs
Buyback programs - october 2022 Monthly communication regarding buyback programs	10/11/2022	Description of buyback programs

Regulated information

322 publications